Telephone: 443-287-7104; Fax: 410-502-7213
Cancer Stem Cells
Article first published online: 28 DEC 2011
Copyright © 2011 AlphaMed Press
Special Issue: 30th Anniversary
Volume 30, Issue 1, pages 89–93, January 2012
How to Cite
Ghiaur, G., Gerber, J. and Jones, R. J. (2012), Concise Review: Cancer Stem Cells and Minimal Residual Disease. STEM CELLS, 30: 89–93. doi: 10.1002/stem.769
Author contributions: G.G., J.G., and R.J.J.: wrote and had final approval of this article.
Disclosure of potential conflicts of interest is found at the end of this article.
First published online in STEM CELLSEXPRESS November 1, 2011.
- Issue published online: 28 DEC 2011
- Article first published online: 28 DEC 2011
- Accepted manuscript online: 1 NOV 2011 02:18PM EST
- Manuscript Accepted: 6 OCT 2011
- Manuscript Received: 30 SEP 2011
- NHLBI. Grant Number: 5T32HL007525-27
- NIH. Grant Numbers: P01 CA15396-26, CA70790-12
- Adult stem cells;
- Clinical translation
Evidence gathered over the past two decades confirms earlier reports that suggested that hematologic malignancies exhibit a hierarchical differentiation structure similar to normal hematopoiesis. There is growing evidence that some solid tumors may also exhibit a differentiation program similar to the normal tissue of origin. Many excellent reviews on the topic of cancer stem cells (CSCs) document the recent explosion of information in the field, particularly highlighting the phenotypic and functional characteristics of these putative cells in vitro. Accordingly, here we only briefly discuss these concepts, and instead primarily examine the potential clinical relevance of CSCs, arguably the major unresolved issue in the field. Although it is generally accepted that CSCs are resistant to chemotherapy in vitro, only recently have data surfaced that suggest a role for these cells in disease relapse. Importantly, cancer cells with a stem cell phenotype have been found to be enriched in minimal residual disease of several malignancies. If the role of CSCs in relapse is confirmed, targeting these cells would hold substantial potential for improving the outcome of cancer patients. STEM CELLS2012;30:89–93